Navigation Links
BioSpecifics Technologies Corp. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Date:12/10/2012

Auxilium is currently partnered with Asahi Kasei Pharma Corporation for the development and commercialization of injectable collagenase for Dupuytren's contracture and Peyronie's disease in Japan and with Actelion Pharmaceuticals Ltd. for these same indications in Canada, Australia, Brazil and Mexico. Pfizer Inc. has marketing rights to XIAPEX® (the EU trade name for XIAFLEX) for Dupuytren's contracture in 46 countries in Eurasia through April 24, 2013.  For more information, please visit www.biospecifics.com.

About RetailInvestorConferences.com:

Since 2010, RetailInvestorConferences.com has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.


'/>"/>
SOURCE RetailInvestorConferences.com
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
2. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
3. BioSpecifics Technologies Corp. Reports Second Quarter 2012 Financial Results
4. BioSpecifics Technologies Corp. To Present at UBS Global Life Sciences Conference
5. BioSpecifics Technologies Corp. Reports Third Quarter 2012 Financial Results
6. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
7. UV Flu Technologies Expands Its International Footprint
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
10. Hologic to Showcase 3D Mammography (Breast Tomosynthesis) and Other Advanced Womens Imaging Technologies at RSNA 2011, the Largest Radiology Show in the World
11. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 “Preparative & Process Chromatography ... Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, ... - Forecasts to 2019” provides a detailed overview ... market trends, and strategies impacting the preparative and ... forecasts of the revenue and share analysis. ...
(Date:12/24/2014)... Earlier this year in a June ... of the Adult Stem Cell Technology Center, LLC ( ... under appreciated unique property of adult tissue stem cells. ... Misunderstood in the Past, Important for the Future,” embodied ... He gave the address at the 4th World Congress ...
(Date:12/24/2014)... On Friday, December 19, 2014, President ... and Continuing Resolution Appropriations Act of 2015, which ... eligible to receive funding through the Congressionally Directed ... of Defense (DoD). The Hydrocephalus Association (HA), working ... is celebrating this victory for the over 1 ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... on methyl mercaptan such as its definition, ... also presents product specification, manufacturing process, and ... regions, technology and applications. The analysis also ... survey, marketing channels, industry development trend and ...
Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: ... focused on endocrine therapy and oncology, today announced ... its targeted cytotoxic peptide conjugate compound, AEZS-108 (formerly ... during yesterday,s poster session at the American Society ...
... ... of work that has made a lasting impact on both agriculture and weed science around the ... exploring new control techniques to benefit farmers. Thousands of students have followed in his footsteps and ... ...
... Time TodayBOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - ... announced the final results of a Randomized Phase 2 ... Society of Clinical Oncology (ASCO) Annual Meeting. Analyses indicated ... combination with docetaxel compared to docetaxel alone - the ...
Cached Biology Technology:AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting 2AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting 3Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 2Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 3Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 4OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer 2OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer 3OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer 4OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer 5OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer 6OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer 7OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer 8
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition ... individuals. Facial recognition system measures the overall facial ... edges, mouth, and the distance between eyes. Facial ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
(Date:12/10/2014)... 2014 CIE San Diego has launched an ... connective tissue that enhances care coordination among social service ... client-level information; earned a second $1 million grant from ... seniors aging in community and; will be recognized as ... th 4-6p. CIE San Diego today ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... dark scene, attention brings to mind specific details of our ... at the Salk Institute for Biological Studies shows that the ... for its role in the control of eye and head ... findings, published in the Dec. 20, 2009, issue of the ...
... in an antibiotic-resistant bacterium is cause for concern, according ... Faculty of 1000 member Dr Johann Pitout, of ... Calgary, urges the medical community to monitor the spread ... to use more powerful antibiotics as a first response. ...
... UCLA scientists have identified a molecular switch that prevents ... 24 edition of the journal Neuron , the discovery ... ultimately leads to death in as little as 10 years. ... Americans, Huntington,s progressively deprives patients of their ability to walk, ...
Cached Biology News:Seeing without looking 2UCLA scientists find molecular switch to prevent Huntington's disease in mice 2
...
Chicken anti-EEA1...
... are membrane-filtered isotonic and enzyme-free aqueous ... cell-conditioning agents in either Ca2+- and ... Ca2+- and Mg2+-free phosphate-buffered saline ... from support substrates and each other ...
Request Info...
Biology Products: